Compass Financial Statements From 2010 to 2025

Compass Biotechnologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Compass Biotechnologies' valuation are provided below:
Market Capitalization
14.3 K
Earnings Share
(0.01)
We have found one hundred twenty available fundamental signals for Compass Biotechnologies, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of Compass Biotechnologies prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 1.6 M. Enterprise Value is estimated to decrease to about 1.6 M
Check Compass Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Biotechnologies' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.1 K or Research Development of 109 K, as well as many indicators such as Price To Sales Ratio of 6.45, Dividend Yield of 0.0 or PTB Ratio of 5.29. Compass financial statements analysis is a perfect complement when working with Compass Biotechnologies Valuation or Volatility modules.
  
Build AI portfolio with Compass Stock
Check out the analysis of Compass Biotechnologies Correlation against competitors.
For more detail on how to invest in Compass Stock please use our How to Invest in Compass Biotechnologies guide.

Compass Biotechnologies Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets95.5 K100.5 K137.6 K
Slightly volatile
Other Current Liabilities378.9 K684.4 K511.9 K
Slightly volatile
Total Current Liabilities1.7 M1.6 M1.2 M
Slightly volatile
Accounts Payable331.6 K315.8 K267.3 K
Slightly volatile
Cash2.9 KK4.7 K
Slightly volatile
Net Receivables55.9 K92.5 K73.8 K
Slightly volatile
Other Stockholder Equity65.9 K69.4 K73.7 K
Pretty Stable
Total Liabilities2.2 M2.1 M1.6 M
Slightly volatile
Total Current Assets129.4 K128.4 K106.9 K
Slightly volatile
Intangible Assets546.1 K632.7 K520.7 K
Slightly volatile
Common Stock28.1 K48.8 K38 K
Slightly volatile
Property Plant Equipment277292374
Slightly volatile
Other Assets55.5 K62.4 K68 K
Slightly volatile
Long Term Debt346.7 K390.1 K425.3 K
Slightly volatile
Short Term Investments25 K28.1 K30.6 K
Slightly volatile
Short and Long Term Debt76.8 K70.4 K95.4 K
Slightly volatile
Short Term Debt76.8 K70.4 K95.4 K
Slightly volatile

Compass Biotechnologies Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.1 K5.4 K80 K
Slightly volatile
Research Development109 K71.5 K92.9 K
Slightly volatile
Total Operating Expenses5.1 K5.4 K106.6 K
Slightly volatile

Compass Biotechnologies Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation38.4 K69.3 K55.8 K
Slightly volatile
Change To Operating Activities5485221.2 K
Slightly volatile
Total Cash From Financing Activities5.5 K5.8 K86.8 K
Slightly volatile
Change To Netincome1.091.1546.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.455.716.1359
Slightly volatile
PTB Ratio5.295.577.9187
Slightly volatile
Days Sales Outstanding11.3511.9512.8164
Slightly volatile
Book Value Per Share0.02470.0260.0343
Slightly volatile
Average Payables42.5 K28.9 K28.1 K
Very volatile
Capex To Depreciation150142148
Slightly volatile
PB Ratio5.295.577.9187
Slightly volatile
EV To Sales6.235.615.9882
Slightly volatile
Inventory Turnover3.542.863.1116
Slightly volatile
Days Of Inventory On Hand124132120
Pretty Stable
Payables Turnover5.497.948.2066
Very volatile
Sales General And Administrative To Revenue0.390.350.3167
Pretty Stable
Average Inventory114.9 K108.1 K97.5 K
Pretty Stable
Capex To Revenue0.00270.00280.0078
Slightly volatile
Cash Per Share0.00410.00430.0737
Slightly volatile
Days Payables Outstanding72.4547.5948.2175
Pretty Stable
Income Quality0.250.260.8523
Slightly volatile
Intangibles To Total Assets0.310.620.6195
Pretty Stable
Current Ratio0.480.510.4836
Slightly volatile
Receivables Turnover33.231.6233.0846
Slightly volatile
Shareholders Equity Per Share0.02470.0260.0343
Slightly volatile
Debt To Equity0.0230.03960.0405
Very volatile
Capex Per Share0.05690.05320.0543
Slightly volatile
Average Receivables39.9 K28.9 K28.3 K
Pretty Stable
Revenue Per Share1.110.870.8525
Pretty Stable
Interest Debt Per Share0.00140.00150.0015
Slightly volatile
Debt To Assets0.010.01210.013
Slightly volatile
Graham Number0.02720.02860.0607
Slightly volatile
Operating Cycle158144135
Pretty Stable
Price Book Value Ratio5.295.577.9187
Slightly volatile
Days Of Payables Outstanding72.4547.5948.2175
Pretty Stable
Pretax Profit Margin0.00480.0050.0126
Slightly volatile
Ebt Per Ebit1.41.211.0805
Slightly volatile
Operating Profit Margin0.00220.00230.0103
Slightly volatile
Effective Tax Rate0.480.690.7291
Very volatile
Company Equity Multiplier4.373.774.1006
Slightly volatile
Total Debt To Capitalization0.02220.03790.0388
Very volatile
Debt Equity Ratio0.0230.03960.0405
Very volatile
Ebit Per Revenue0.00220.00230.0103
Slightly volatile
Quick Ratio0.480.510.472
Slightly volatile
Net Income Per E B T1.040.991.0489
Slightly volatile
Cash Ratio0.06270.0660.0958
Slightly volatile
Cash Conversion Cycle85.6496.4186.3801
Pretty Stable
Operating Cash Flow Sales Ratio0.06390.06730.0998
Slightly volatile
Days Of Inventory Outstanding124132120
Pretty Stable
Days Of Sales Outstanding11.3511.9512.8164
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.051.371.4417
Very volatile
Price To Book Ratio5.295.577.9187
Slightly volatile
Fixed Asset Turnover648617637
Slightly volatile
Debt Ratio0.010.01210.013
Slightly volatile
Price Sales Ratio6.455.716.1359
Slightly volatile
Asset Turnover2.233.243.3253
Pretty Stable
Net Profit Margin0.00110.00120.0053
Slightly volatile
Gross Profit Margin0.650.640.5756
Pretty Stable
Price Fair Value5.295.577.9187
Slightly volatile

Compass Biotechnologies Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.6 M1.7 M1.4 M
Slightly volatile
Enterprise Value1.6 M1.7 M1.4 M
Slightly volatile

About Compass Biotechnologies Financial Statements

Investors use fundamental indicators, such as Compass Biotechnologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Compass Biotechnologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Sales General And Administrative To Revenue 0.35  0.39 
Revenue Per Share 0.87  1.11 

Currently Active Assets on Macroaxis

When determining whether Compass Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compass Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compass Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compass Biotechnologies Stock:
Check out the analysis of Compass Biotechnologies Correlation against competitors.
For more detail on how to invest in Compass Stock please use our How to Invest in Compass Biotechnologies guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Real Estate Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Biotechnologies. If investors know Compass will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compass Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(0.03)
The market value of Compass Biotechnologies is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Compass Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Biotechnologies' market value can be influenced by many factors that don't directly affect Compass Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compass Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Compass Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compass Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.